Could a Mitochondria-Targeting pill ease asthma in obesity?

NCT ID NCT04026711

Completed Symptom relief Sponsor: University of Vermont Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested whether MitoQ, a drug that targets cell energy centers, can improve airway reactivity in 47 obese adults with poorly controlled asthma. Participants took MitoQ or a placebo daily for 12 weeks. The study aimed to see if MitoQ could help control asthma symptoms in this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MitoQ (mitoquinol)
What this could lead to: If it works, MitoQ could offer a new way to improve asthma control in people with obesity by targeting metabolic dysfunction.
What could go wrong: This is a small, early-phase pilot study with only 47 participants. Results may not apply to all asthma patients, and the treatment may not show significant benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA OBESITY

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27710, United States
University of Vermont

Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.